The drug developer has no approved products or revenue yet, but the IPO could extend its cash runway by nearly six years.

Its controller leadership, thin float, and high valuation could make for an unpredictable debut.

Its product focus and logistics upgrades have helped lift profitability and operational efficiency.

The listing will test investor appetite for decision intelligence as the AI narrative reaches a high point.

The planned IPO comes as the memory company expands beyond consumer modules into edge AI and enterprise storage.

The financing is being viewed as a pre-IPO round, with Kling’s pre-money valuation equal to about two-thirds of Kuaishou’s market value.

The company is moving beyond traditional robots into higher-value systems designed for smart manufacturing.

Cockpit-driving integrated products sit at the center of the company’s pitch.